About Abattis Bioceuticals (CNSX:ATT)
Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.
Industry, Sector and Symbol
Trailing P/E Ratio-5.8
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-402.39%
Return on Assets-361.99%
Abattis Bioceuticals (CNSX:ATT) Frequently Asked Questions
What is Abattis Bioceuticals' stock symbol?
Abattis Bioceuticals trades on the CNSX under the ticker symbol "ATT."
Who are Abattis Bioceuticals' key executives?
Abattis Bioceuticals' management team includes the folowing people:
- Robert Abenante CPA, President, Chief Executive Officer, Director (Age 33)
- David Whitney, Chief Financial Officer
- Rene David, Chief Operating Officer, Director
- Christopher P. Cherry, Corporate Controller (Age 40)
- Hugh Oswald, IR Contact Officer
- Christina Boddy, Corporate Secretary
- Peter Gordon, Director
- James Irving, Director
- Shuang Xie, Director
- Guy P. Dancosse QC, Independent Director
Has Abattis Bioceuticals been receiving favorable news coverage?
Media stories about ATT stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Abattis Bioceuticals earned a news sentiment score of 0.08 on Accern's scale. They also assigned media headlines about the company an impact score of 45.67 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
What is Abattis Bioceuticals' stock price today?
One share of ATT stock can currently be purchased for approximately C$0.29.
How big of a company is Abattis Bioceuticals?
Abattis Bioceuticals has a market capitalization of C$80.40 million.
How can I contact Abattis Bioceuticals?
Abattis Bioceuticals' mailing address is 224-970 Burrard St, VANCOUVER, BC V6Z 2R4, Canada. The company can be reached via phone at +1-604-3360881.
MarketBeat Community Rating for Abattis Bioceuticals (ATT)MarketBeat's community ratings are surveys of what our community members think about Abattis Bioceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Abattis Bioceuticals (CNSX:ATT) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Earnings History for Abattis Bioceuticals (CNSX:ATT)
No earnings announcements for this company have been tracked by MarketBeat.com
Abattis Bioceuticals (CNSX:ATT) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Abattis Bioceuticals (CNSX:ATT)
No dividend announcements for this company have been tracked by MarketBeat.com
Abattis Bioceuticals (CNSX ATT) Insider Trading and Institutional Ownership History
Abattis Bioceuticals (CNSX ATT) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Abattis Bioceuticals (CNSX ATT) News Headlines
Abattis Bioceuticals (CNSX:ATT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Abattis Bioceuticals (CNSX ATT) Stock Chart for Wednesday, March, 21, 2018